Today’s Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks

Stock Research Monitor: SLS, TTPH, and RARE

LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on SGEN sign up now at www.wallstequities.com/registration. On Wednesday, June 06, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday’s session. The NASDAQ Composite ended the day at 7,689.24, up 0.67%; the Dow Jones Industrial Average edged 1.40% higher, to finish at 25,146.39; and the S&P 500 closed at 2,772.35, up 0.86%. This Thursday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Seattle Genetics Inc. (NASDAQ: SGEN), SELLAS Life Sciences Group Inc. (NASDAQ: SLS), Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Seattle Genetics

On Wednesday, shares in Bothell, Washington headquartered Seattle Genetics Inc. recorded a trading volume of 1.18 million shares, which was above their three months average volume of 926.67 thousand shares. The stock ended the session 3.66% higher at $65.36. The Company’s shares have gained 20.93% in the last month and 16.20% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 21.74% and 18.59%, respectively. Moreover, shares of Seattle Genetics, which focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide, have a Relative Strength Index (RSI) of 80.46. Get the full research report on SGEN for free by clicking below at:

www.wallstequities.com/registration/?symbol=SGEN

SELLAS Life Sciences Group

New York headquartered SELLAS Life Sciences Group Inc.’s stock closed the day 2.55% lower at $5.36 with a total trading volume of 103,259 shares. The Company’s shares have advanced 5.51% in the previous three months. The stock is trading below its 50-day moving average by 4.59%. Additionally, shares of the Company, which focuses on the development of novel cancer immunotherapies for various cancer indications, have an RSI of 43.97. Free research on SLS can be accessed at:

www.wallstequities.com/registration/?symbol=SLS

Tetraphase Pharmaceuticals

Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. recorded a trading volume of 234,928 shares. The stock ended yesterday’s trading session 1.61% higher at $3.79. The Company’s shares have advanced 42.48% over the previous three months. The stock is trading above its 50-day moving average by 13.38%. Furthermore, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 62.16. Visit WallStEquities.com now and sign up for the free research on TTPH at:

www.wallstequities.com/registration/?symbol=TTPH

Ultragenyx Pharmaceutical

Novato, California headquartered Ultragenyx Pharmaceutical Inc.’s stock finished Thursday’s session 6.17% higher at $77.58 with a total trading volume of 641,330 shares. The Company’s shares have advanced 33.85% in the last month, 46.88% over the previous three months, and 35.46% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 33.90% and 48.45%, respectively. Additionally, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 82.39.

On May 11th, 2018, research firm Barclays upgraded the Company’s stock rating from ‘Equal Weight’ to ‘Overweight’ while revising its previous target price from $62 a share to $74 a share. The free technical report on RARE is available at:

www.wallstequities.com/registration/?symbol=RARE

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501983